THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, December 01, 2021
FREMONT, CA:In a Phase II clinical trial, BioNTech has treated the first colorectal cancer patient with their customised messenger RNA (mRNA) cancer vaccine BNT122 (autogenecevumeran, RO7198457). The trial has already begun in the United States, Germany, Spain, and Belgium. According to BioNTech, roughly 200 patients will be included in the study to compare the efficacy of RO7198457 (BNT122) to the current standard of care for these high-risk patients, which is watchful waiting following surgery and adjuvant chemotherapy.
Autogenecevumeran is the lead candidate from BioNTech's mRNA-based cancer vaccination technology. It is an individualised neoantigen specific immunotherapy (iNeST). The open-label Phase II trial is looking into autogenecevumeran in patients with stage II/III colorectal cancer after surgical resection and adjuvant chemotherapy.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
A portion of these patients are predicted to suffer a recurrence of their tumour within two to three years following surgery; those at high risk for recurrence will be identified early on in the clinical trial using a blood test that detects circulating tumour DNA (ctDNA).
In this high-risk patient population, the Phase II trial will compare the efficacy of autogenecevumeran as a single drug versus standard of care watchful waiting. The study's primary goal is disease-free survival (DFS). Relapse-free survival (RFS), overall survival (OS), and safety are secondary goals. The trial's first patient was treated at a clinical location in Europe.
The Phase II trial is based on the outcomes of a Phase Ia/Ib basket trial in solid tumour patients assessing autogenecevumeran as a single drug and in combination with atezolizumab, an anti-PD-L1 antibody.
The results suggest that neoantigen-specific T cell responses can be induced, as well as a controlled safety profile and objective responses as a sign of therapeutic efficacy. In addition to the existing Phase II experiment, BioNTech has started an epidemiology investigation to explore ctDNA status in patients with stage II/III colorectal cancer after resection or before adjuvant treatment in order to identify people who could be potential Phase II trial participants.
More in News